Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07454473) titled 'Edaravone and Dexborneol Sublingual Tablet for Treating Chemotherapy- Induced Cognitive Impairment Study' on March 2.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Chuansheng Zhao
Condition:
Chemo Brain
Intervention:
Drug: Edaravone Dexborneol
Recruitment Status: Recruiting
Phase: Phase 4
Date of First Enrollment: March 2, 2026
Target Sample Size: 80
Countries of Recruitment:
China
To know more, visit https://clinica...